Multitargeted protein kinase inhibitors have shown great promise in cancer therapy, but the selectivity profiles of these compounds have largely relied on serendipity or 'off-target' activities rather than rational drug design. Purposefully designed compounds with activity against multiple target kinases bring us a step closer to personalized medicine.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Clustered Distribution of Natural Product Leads of Drugs in the Chemical Space as Influenced by the Privileged Target-Sites
Scientific Reports Open Access 20 March 2015
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. Science 298, 1912–1934 (2002).
Knight, Z.A. & Shokat, K.M. Chem. Biol. 12, 621–637 (2005).
Bain, J. et al. Biochem. J. 408, 297–315 (2007).
Apsel, B. et al. Nat. Chem. Biol. 4, 691–699 (2008).
Sebolt-Leopold, J.S. & English, J.M. Nature 441, 457–462 (2006).
Petrelli, A. & Giordano, S. Curr. Med. Chem. 15, 422–432 (2008).
Quintas-Cardama, A., Kantarjian, H. & Cortes, J. Nat. Rev. Drug Discov. 6, 834–848 (2007).
Marone, R., Cmiljanovic, V., Giese, B. & Wymann, M.P. Biochim. Biophys. Acta 1784, 159–185 (2008).
Hayakawa, M. et al. Bioorg. Med. Chem. Lett. 17, 2438–2442 (2007).
Fan, Q.W. et al. Cancer Cell 9, 341–349 (2006).
Raynaud, F.I. et al. Cancer Res. 67, 5840–5850 (2007).
Maira, S.M. et al. Mol. Cancer Ther. 7, 1851–1863 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
B.V. is an advisor to Intellikine, and N.T. is a paid employee of Piramed Pharma.
Rights and permissions
About this article
Cite this article
Bilanges, B., Torbett, N. & Vanhaesebroeck, B. Killing two kinase families with one stone. Nat Chem Biol 4, 648–649 (2008). https://doi.org/10.1038/nchembio1108-648
Issue Date:
DOI: https://doi.org/10.1038/nchembio1108-648
This article is cited by
-
Clustered Distribution of Natural Product Leads of Drugs in the Chemical Space as Influenced by the Privileged Target-Sites
Scientific Reports (2015)
-
Synthesis and anti-proliferative activity evaluation of sorafenib derivatives with a 3-arylacryloyl hydrazide unit
Medicinal Chemistry Research (2015)
-
Measuring and interpreting the selectivity of protein kinase inhibitors
Journal of Chemical Biology (2009)
